Skip to main content
Premium Trial:

Request an Annual Quote

Millennium to Acquire Cambridge Discovery for $53M

Premium

Millennium Pharmaceuticals has agreed to acquire Cambridge Discovery Chemistry, a wholly-owned subsidiary of the UK’s Oxford Molecular Group, for $53 million in cash.

To finance the deal, Millennium said it would sell securities in a private placement.

Based in Cambridge, Mass., Millennium said the acquisition would help it to build its medicinal and computational chemistry infrastructure in order to to accelerate its downstream drug discovery program.

“This enhanced discovery research capability will be invaluable not only in advancing Millennium’s proprietary pipeline, but in Millennium’s recently announced strategic alliance with Aventis, a collaboration for the discovery, development, and commercialization of anti-inflammatory drugs and the development of drug discovery technologies,” said Mark Levin, chairman and CEO of Millennium.

The deal will more than double Millennium’s chemistry staff to 150. Millennium, which currently employs more than 1,000 people, said it has plans for further growth.

Cambridge Discovery Chemistry will continue to operate in the United Kingdom.

Filed under

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.